{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=118", "query": { "condition": "Relapsed, Refractory Malignant Neoplasms", "page": 118 }, "page_size": 10 }, "pagination": { "page": 118, "page_size": 10, "total_count": 3448, "total_pages": 345, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=119&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=117&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T13:38:25.747Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05259839", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 283, "start_date": "2022-10-20", "completion_date": "2033-09", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 15, "location_summary": "Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05259839" }, { "nct_id": "NCT02199665", "title": "Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "selinexor", "type": "DRUG" }, { "name": "carfilzomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2014-06-12", "completion_date": "2025-10-25", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Chicago, Illinois • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02199665" }, { "nct_id": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia", "Leukemia, Acute Myeloid", "Myeloid Leukemia, Acute", "Leukemia, Myeloid, Acute", "Acute Myelogenous Leukemia", "Leukemia, Acute Myelogenous", "Myelogenous Leukemia, Acute", "AML", "Bone Marrow Transplant" ], "interventions": [ { "name": "Iomab-B", "type": "DRUG" }, { "name": "Conventional Care", "type": "DRUG" }, { "name": "HCT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Actinium Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 153, "start_date": "2016-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 22, "location_summary": "Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02665065" }, { "nct_id": "NCT00932698", "title": "Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed and Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2009-10-12", "completion_date": "2017-05-23", "has_results": true, "last_update_posted_date": "2019-08-07", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 5, "location_summary": "Tampa, Florida • Atlanta, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00932698" }, { "nct_id": "NCT06191887", "title": "B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Autologous BAFFR-targeting CAR T Cells", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-03-18", "completion_date": "2040-12-31", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06191887" }, { "nct_id": "NCT01165112", "title": "Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2010-09", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01165112" }, { "nct_id": "NCT00003245", "title": "Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "15 Years to 75 Years" }, "enrollment_count": 50, "start_date": "1998-02-18", "completion_date": "2004-07-30", "has_results": false, "last_update_posted_date": "2018-11-15", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003245" }, { "nct_id": "NCT04855136", "title": "Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "BB2121", "type": "BIOLOGICAL" }, { "name": "CC-220", "type": "DRUG" }, { "name": "BMS-986405", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-06-01", "completion_date": "2025-04-25", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 15, "location_summary": "Birmingham, Alabama • San Francisco, California • Jacksonville, Florida + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04855136" }, { "nct_id": "NCT04745234", "title": "Mogamulizumab Q4week Dosing in Participants With R/R CTCL", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T-Cell Lymphoma, Relapsed", "Cutaneous T-Cell Lymphoma Refractory" ], "interventions": [ { "name": "Mogamulizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-08-16", "completion_date": "2025-05", "has_results": false, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 7, "location_summary": "Duarte, California • Irvine, California • Stanford, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745234" }, { "nct_id": "NCT01829711", "title": "Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Hairy Cell" ], "interventions": [ { "name": "Moxetumomab pasudotox", "type": "DRUG" }, { "name": "IV Bag Protectant for Moxetumomab pasudotox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 80, "start_date": "2013-04-29", "completion_date": "2019-04-29", "has_results": true, "last_update_posted_date": "2020-04-08", "last_synced_at": "2026-11-07T13:38:25.747Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Miami, Florida + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01829711" } ] }